SynthesisDigestive diseases and sciences2002
Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.
Synthesis in Digestive diseases and sciences, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 6 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Systematic review and meta-analysis: association between obesity/overweight and surgical complications in IBD.International journal of colorectal disease · 2022Pooled it
- Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis.International journal of colorectal disease · 2021Pooled it
- Pooled it
- Pooled it
- Crohn's disease.BMJ clinical evidence · 2011Pooled it
- Crohn's disease.BMJ clinical evidence · 2007Pooled it
- Trial
- Double-blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients.Digestive diseases and sciences · 2006Trial
- No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases.International journal of colorectal disease · 2003Trial
- Design and Preliminary In Vivo Evaluation of J2H-1802, a Hybrid Compound Derived from 5-ASA and MMF, in a DSS-Induced Colitis Mouse Model.Pharmaceuticals (Basel, Switzerland) · 2026Article
- NDP52 and its emerging role in pathogenesis.Cell death & disease · 2025Review
- Advances in Colon-targeted Drug Delivery Systems: Innovative Strategies for Treating Colonic Disorders and Prospects for the Future.Current pharmaceutical biotechnology · 2025Review
- Nanomedicine: The new trend and future of precision medicine for inflammatory bowel disease.Chinese medical journal · 2024Review
- Common Mistakes in Managing Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2024Review
- Therapeutic Effect of HDAC5 Binding and Cell Penetrating Peptide for the Treatment of Inflammatory Bowel Disease.Tissue engineering and regenerative medicine · 2023Article
- Chitosan functionalized MnCommunications biology · 2023Article
- In silico analysis of3 Biotech · 2022Article
- Effect of mesalazine combined with probiotics on inflammation and immune function of patients with inflammatory bowel disease.American journal of translational research · 2022Article
- Description of the inflammatory bowel disease natural history in Tehran province, Iran: Mixed panel approaches.Gastroenterology and hepatology from bed to bench · 2021Article
- The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.